A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology [0.03%]
皮肤病学 topical药物递送系统的实用指南
Andrei Metelitsa,Isabelle Delorme,Daniel O&#x;Sullivan et al.
Andrei Metelitsa et al.
Dermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows ...
Review
Skin therapy letter. 2023 Sep;28(5):5-11. DOI: 2023
Ashley O&#x;Toole,Melinda Gooderham
Ashley O&#x;Toole
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and toler...
Review
Skin therapy letter. 2023 Sep;28(5):1-4. DOI: 2023
Lyn Guenther
Lyn Guenther
The lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, mo...
Nicole Salame,Ariel E Eber,Jeffrey Dover
Nicole Salame
Botulinum toxin A (BoNTA) is produced by Clostridium botulinum and widely used for aesthetic indications requiring neuromuscular blockade. For dynamic facial lines, BoNTA is effective and safe, but also temporary, requiring repeat injection...
Review
Skin therapy letter. 2023 Jul;28(4):1-3. DOI: 2023
Nadia Kashetsky,Irina Turchin
Nadia Kashetsky
As systemic administration of Janus kinase-inhibitors is associated with safety concerns, local alternatives, such as topical ruxolitinib, have been developed. This review summarizes utilization of topical ruxolitinib in dermatology. A lite...
Review
Skin therapy letter. 2023 May;28(3):8-13. DOI: 2023
The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions [0.03%]
治疗斑秃的Janus激酶抑制剂药物进展及未来方向展望
Jeff Donovan
Jeff Donovan
Oral Janus kinase (JAK) inhibitors now have a position as first-line agents for treating advanced alopecia areata. Oral JAK inhibitors are considerably more effective than topical JAK inhibitors, although topical agents may still have a val...
Review
Skin therapy letter. 2023 May;28(3):1-7. DOI: 2023
Austinn C Miller,Susuana Adjei,Laurie A Temiz et al.
Austinn C Miller et al.
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand how dermatologists can com...
Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada [0.03%]
加拿大氯甲基磺酸酯凝胶治疗蕈样肉芽肿(皮肤T细胞淋巴瘤)
Robert Gniadecki,Emilia Paron
Robert Gniadecki
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing almost 50% of all lymphomas arising in the skin. There is an unmet need in the treatment of MF in Canada, as current available therapies for ea...
Austinn C. Miller,Susuana Adjei,Laurie A. Temiz et al.
Austinn C. Miller et al.
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand the mechanisms at play tha...
Abrahim Abduelmula,Brian D Rankin,Asfandyar Mufti et al.
Abrahim Abduelmula et al.
Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It wa...
Review
Skin therapy letter. 2023 Jan;28(1):1-6. DOI: 2023